APA (7th ed.) Citation

Bleibtreu, A., Bennis, Y., Dinh, A., Dupont, H., Friggeri, A., Jeannot, K., . . . Zahar, J. (2026). Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement. Infectious Diseases & Therapy, 15(3), 835. https://doi.org/10.1007/s40121-026-01301-y

Chicago Style (17th ed.) Citation

Bleibtreu, Alexandre, Youssef Bennis, Aurélien Dinh, Hervé Dupont, Arnaud Friggeri, Katy Jeannot, Eric Kipnis, and Jean-Ralph Zahar. "Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter Baumannii, Pseudomonas Aeruginosa, and Stenotrophomonas Maltophilia) Infections: An Expert Statement." Infectious Diseases & Therapy 15, no. 3 (2026): 835. https://doi.org/10.1007/s40121-026-01301-y.

MLA (9th ed.) Citation

Bleibtreu, Alexandre, et al. "Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter Baumannii, Pseudomonas Aeruginosa, and Stenotrophomonas Maltophilia) Infections: An Expert Statement." Infectious Diseases & Therapy, vol. 15, no. 3, 2026, p. 835, https://doi.org/10.1007/s40121-026-01301-y.